Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy

G. Piperno, M. Cosimelli, R. Perrone Donnorso, R. Mancini, S. Buglioni, F. Novelli, I. Sperduti, V. Zerbini, C. Garufi, Marcella Mottolese

Research output: Contribution to journalArticlepeer-review


Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalJournal of Chemotherapy
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004


  • Adjuvant therapy
  • Advanced rectal cancer
  • Bcl-2
  • p53
  • Prognosis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)


Dive into the research topics of 'Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy'. Together they form a unique fingerprint.

Cite this